SANTA CRUZ BIOTECHNOLOGY, INC.

DOCK 180 (1700-1769): sc-4481 WB

SANTA CRUZ BIOTECHNOLOGY
The Power to Question

BACKGROUND

The v-Crk oncogene product shares homologous amino acid sequences, designated Src homology region 2 (SH2) and SH3, respectively, with many molecules involved in signal transduction. The v-Crk cellular homolog, c-Crk, is a member of a newly emerging class of genes including Nck and GRB2/ASH which encode proteins that consist primarily of SH2 and SH3 domains. Two distinct human c-Crk cDNAs, designated Crk I and Crk II, respectively, have been identified and shown to represent alternative splice products of c-Crk. The major translational product of c-Crk I has been identified as a 28 kDa variably expressed protein, while c-Crk II encodes a widely expressed 40 kDa protein and a more variably expressed 42 kDa protein. The major c-Crk transforming activity appears associated with c-Crk I p28 expression. DOCK 180, a 180 kDa protein downstream of Crk, has been identified as a major Crk-associated protein. When DOCK 180 is recruited to the plasma membrane from a cytoplasmic reservoir, presumably by Crk, changes in cellular morphology and spindle formation occur, suggesting DOCK 180 to be a Crk effector molecule.

REFERENCES

1. Mayer, B.J. and Hanafusa, H. 1990. Association of the v-Crk oncogene product with phosphotyrosine-containing proteins and protein kinase activity. Proc. Natl. Acad. Sci. USA 87: 2638-2642.
2. Matsuda, M., Mayer, B.J., Fukui, Y., and Hanafusa, H. 1990. Binding of transforming protein, P47gag-Crk, to a broad range of phosphotyrosine-containing proteins. Science 248: 1537-1539.
3. Mayer, B.J. and Hanafusa, H. 1990. Mutagenic analysis of the v-Crk oncogene: requirement for SH2 and SH3 domains, and correlation between increased cellular phosphotyrosine and transformation. J. Virol. 64: 3581-3589.
4. Matsuda, M., Tanaka, S., Nagata, S., Kojima, A., Kurata, T., and Shibuya, M. 1992. Two species of human Crk cDNA encode proteins with distinct biological activities. Mol. Cell. Biol. 12: 3482-3489.
5. Matsuda, M., Reichman, C.T., and Hanafusa, H. 1992. Biological and biochemical activity of v-Crk chimeras containing the SH2/SH3 regions of phosphatidylinositol-specific phospholipase C-g and Src. J. Virol. 66: 115-121.
6. Tanaka, S., Hattori, S., Kurata, T., Nagashima, K., Fukui, Y., Nakamura, S., and Matsuda, M. 1993. Both the SH2 and SH3 domains of human Crk protein are required for neuronal differentiation of PC12 cells. Mol. Cell. Biol. 13: 4409-4415.
7. Hasegawa, H., Kiyokawa, E., Tanaka, S., Nagashima, K., Gotoh, N., Shibuya, M., Kurata, T., and Matsuda, M. 1996. DOCK180, a major Crk-binding protein, alters cell morphology upon translocation to the cell membrane. Mol. Cell. Biol. 16: 1770-1776.

SOURCE

DOCK 180 (1700-1769) is expressed in *E. coli* as a 35 kDa tagged fusion protein corresponding to amino acids 1700-1769 of DOCK 180 of human origin.

PRODUCT

DOCK 180 (1700-1769) is purified from bacterial lysates (>98%) by glutathione agarose affinity chromatography; supplied as 10 µg in 0.1 ml SDS-PAGE loading buffer.

APPLICATIONS

DOCK 180 (1700-1769) is suitable as a Western blotting control for sc-5625 and sc-13163.

STORAGE

Store at -20° C; stable for one year from the date of shipment.

RESEARCH USE

For research use only, not for use in diagnostic procedures.